| Literature DB >> 17392385 |
Debbie Saslow1, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener, Robert A Smith, Ellen Warner, Martin Yaffe, Kimberly S Andrews, Christy A Russell.
Abstract
New evidence on breast Magnetic Resonance Imaging (MRI) screening has become available since the American Cancer Society (ACS) last issued guidelines for the early detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed new recommendations for women at different defined levels of risk. Screening MRI is recommended for women with an approximately 20-25% or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin disease. There are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mammography. Diagnostic uses of MRI were not considered to be within the scope of this review.Entities:
Mesh：
Year: 2007 PMID： 17392385 DOI： 10.3322/canjclin.57.2.75
Source DB: PubMed Journal: CA Cancer J Clin ISSN： 0007-9235 Impact factor: 508.702